64 related articles for article (PubMed ID: 27940897)
1. CORRIGENDUM to Abnormal thymic maturation and lymphoproliferation in MRL-Faslpr/lpr mice can be partially reversed by synthetic oligonucleotides: implications for systemic lupus erythematosus and autoimmune lymphoproliferative syndrome.
Lupus; 2017 Jun; 26(7):787. PubMed ID: 27940897
[No Abstract] [Full Text] [Related]
2. Abnormal thymic maturation and lymphoproliferation in MRL-Fas
Ashman RF; Singh N; Lenert PS
Lupus; 2017 Jun; 26(7):734-745. PubMed ID: 27837196
[TBL] [Abstract][Full Text] [Related]
3. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.
Goury A; Meghraoui-Kheddar A; Belmokhtar K; Vuiblet V; Ortillon J; Jaisson S; Devy J; Le Naour R; Tabary T; Cohen JH; Schmidt AM; Rieu P; Touré F
J Immunol; 2015 Apr; 194(8):3612-22. PubMed ID: 25762779
[TBL] [Abstract][Full Text] [Related]
4. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
Faust J; Menke J; Kriegsmann J; Kelley VR; Mayet WJ; Galle PR; Schwarting A
Arthritis Rheum; 2002 Nov; 46(11):3083-95. PubMed ID: 12428253
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
6. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice.
Takahashi S; Fossati L; Iwamoto M; Merino R; Motta R; Kobayakawa T; Izui S
J Clin Invest; 1996 Apr; 97(7):1597-604. PubMed ID: 8601623
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of the autoimmune Yaa and lpr genes on the acceleration of lupus-like syndrome in MRL/MpJ mice.
Merino R; Shibata T; De Kossodo S; Izui S
Eur J Immunol; 1989 Nov; 19(11):2131-7. PubMed ID: 2599002
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease.
Cauwe B; Martens E; Sagaert X; Dillen C; Geurts N; Li S; Mertens J; Thijs G; Van den Steen PE; Heremans H; De Vos R; Blockmans D; Arnold B; Opdenakker G
J Autoimmun; 2011 May; 36(3-4):239-52. PubMed ID: 21376533
[TBL] [Abstract][Full Text] [Related]
9. Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus.
Zeller GC; Hirahashi J; Schwarting A; Sharpe AH; Kelley VR
J Am Soc Nephrol; 2006 Jan; 17(1):122-30. PubMed ID: 16291836
[TBL] [Abstract][Full Text] [Related]
10. Analysis of granulomatous arteritis in MRL/Mp autoimmune disease mice bearing lymphoproliferative genes. The use of mouse genetics to dissociate the development of arteritis and glomerulonephritis.
Nose M; Nishimura M; Kyogoku M
Am J Pathol; 1989 Aug; 135(2):271-80. PubMed ID: 2782373
[TBL] [Abstract][Full Text] [Related]
11. Oncogene expression in autoimmune mice.
Mountz JD; Mushinski JF; Mark GE; Steinberg AD
J Mol Cell Immunol; 1985; 2(3):121-31. PubMed ID: 3916923
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of mesenchymal stem cells ameliorates secondary osteoporosis through interleukin-17-impaired functions of recipient bone marrow mesenchymal stem cells in MRL/lpr mice.
Ma L; Aijima R; Hoshino Y; Yamaza H; Tomoda E; Tanaka Y; Sonoda S; Song G; Zhao W; Nonaka K; Shi S; Yamaza T
Stem Cell Res Ther; 2015 May; 6(1):104. PubMed ID: 26012584
[TBL] [Abstract][Full Text] [Related]
13. Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse.
Zhou T; Bluethmann H; Eldridge J; Berry K; Mountz JD
J Immunol; 1993 Apr; 150(8 Pt 1):3651-67. PubMed ID: 7682246
[TBL] [Abstract][Full Text] [Related]
14. beta2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice.
Christianson GJ; Blankenburg RL; Duffy TM; Panka D; Roths JB; Marshak-Rothstein A; Roopenian DC
J Immunol; 1996 Jun; 156(12):4932-9. PubMed ID: 8648144
[TBL] [Abstract][Full Text] [Related]
15. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
16. Alterations in leucocyte trafficking in lupus-prone mice: an examination of the MRL/faslpr mouse.
Hickey MJ
Immunol Cell Biol; 2003 Oct; 81(5):390-6. PubMed ID: 12969327
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice.
Stock AD; Wen J; Doerner J; Herlitz LC; Gulinello M; Putterman C
J Neuroinflammation; 2015 Nov; 12():205. PubMed ID: 26546449
[TBL] [Abstract][Full Text] [Related]
18. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
[TBL] [Abstract][Full Text] [Related]
20. Studies of lymphoproliferation in MRL-lpr/lpr mice.
Smathers PA; Santoro TJ; Chused TM; Reeves JP; Steinberg AD
J Immunol; 1984 Oct; 133(4):1955-61. PubMed ID: 6332142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
